Background & Aims: The natural history of nonalcoholic fatty liver disease (NAFLD) in the
community remains unknown. We sought to determine survival and liver-related morbidity …

Nonalcoholic steatohepatitis (NASH) may present with increased hepatic fibrosis progressing
to end‐stage liver disease. No factors that determine increasing fibrosis and histologically …

… Locke GR 3rd, Therneau TM, Ludwig J, Dickson ER, Lindor KD. … RA, Dickson ER, Lindor
KD. Long-term ursodeoxycholic acid … Gossard AA, Lindor KD. Development of autoimmune …

BACKGROUND & AIMS:: The pathogenesis of nonalcoholic steatohepatitis (NASH) remains
poorly understood. Although apoptosis is a common mechanism of liver injury, the extent …

BACKGROUND/AIMS: The histological course of nonalcoholic fatty liver disease (NAFLD)
remains undescribed. Therefore, we examined the liver histology of NAFLD patients who had …

Background Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress
to cirrhosis and death despite ursodiol therapy. Alkaline phosphatase and bilirubin levels …

No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH).
Ursodeoxycholic acid (UDCA) has been suggested to be of benefit based on open …

… Contributors: Leon Adams was the primary author, Paul Angulo provided scientific input,
and Keith Lindor was responsible for oversight, editing and scientific content. All of the authors …

Non–alcohol–induced steatohepatitis (NASH) is characterized by elevated serum
aminotransferase activities with hepatic steatosis, inflammation, and occasionally fibrosis that may …

… Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD. Highdose ursodeoxycholic
acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:…